March 03, 2025 02:44 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Crucial to have Trump’s support, says Zelenskyy a day after fiery White House exchange | 'We're looking for peace, Zelenskyy wants Russia-Ukraine war to continue': Donald Trump after White House public spat | Volodymyr Zelenskyy refuses to apologise to Donald Trump after public spat over Russia-Ukraine war | 'Make a deal or we are out': Donald Trump tells Volodymyr Zelenskyy at White House | Himachal govt seeks fund from temple to support welfare schemes, BJP calls move 'shocking' | Injustice to opposition MLAs: Atishi writes to Delhi Assembly Speaker on suspension of 21 AAP lawmakers | We will leave for US tomorrow: Father of Indian student Neelam Shinde after urgent visa grant | 'Not joining BJP or floating any party': Abhishek Banerjee dismisses rumours of his split from TMC | Pune bus rape accused arrested after 75-hour manhunt | Finance Secretary Tuhin Kanta Pandey appointed as new SEBI chief
Pixabay

India's Glenmark launches first oral antiviral drug FabiFlu to treat COVID-19 patients

| @indiablooms | Jun 21, 2020, at 01:23 pm

New Delhi/IBNS: Amid the massive spike in number of cases, India-based pharmaceutical company 'Glenmark Pharmaceuticals' has launched antiviral drug Favipiravir, to be sold under the brand name FabiFlu, for the treatment of patients having mild to moderate COVID-19 symptoms.

The company received manufacturing and marketing rights after getting approval from the Drugs Controller General of India (DCGI) on Friday.

FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19.

During clinical trials, the medicine has produced up to 88% improvement in mild to moderate coronavirus patients.

It will be available across the country by early next week, the company said on Saturday.

A pack of 34 oral tablets of 200 mg each will be sold at a cost of Rs 3,500 and the cost of the 14-day treatment will be an estimated Rs 14,000.

“This approval comes at a time when Covid-19 cases in India are spiralling like never before, putting tremendous pressure on our healthcare system,” Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.

India has so far registered over 4 lakhs cases of the highly contagious virus including 12,000 deaths.

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.